Your browser doesn't support javascript.
loading
Review of the recent advances of pyrazole derivatives as selective COX-2 inhibitors for treating inflammation.
Ghoneim, Mohammed M; Abdelgawad, Mohamed A; Elkanzi, Nadia A A; Bakr, Rania B.
Afiliação
  • Ghoneim MM; Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah, 13713, Saudi Arabia.
  • Abdelgawad MA; Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, 72388, Saudi Arabia. mhdgwd@ju.edu.sa.
  • Elkanzi NAA; Chemistry Department, College of Science, Jouf University, P.O. Box: 2014, Sakaka, Saudi Arabia.
  • Bakr RB; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Beni-Suef University, 62514, Beni-Suef, Egypt. raniabakr@ymail.com.
Mol Divers ; 2024 Jul 16.
Article em En | MEDLINE | ID: mdl-39014146
ABSTRACT
Pyrazole heterocycle is regarded as an extremely significant agent for the therapy of inflammation. Celecoxib, lonazolac, deracoxib, and phenylbutazone are examples of commercially approved pyrazole drugs with COX-2 inhibitory potential for curing inflammation. There have been recently many reviews for the biological significance of pyrazole derivatives. This review talks about pyrazole derivatives with anti-inflammatory activity and also sheds the light on the recent updates on pyrazole research with an emphasis on some synthetic pathways utilized to construct this privileged scaffold and structure activity relationship that accounts for the anti-inflammatory activity in an attempt to pave the opportunity for medicinal chemists to develop novel anti-inflammatory agents with better COX-2 selectivity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article